Praxis Precision Medicines Inc. (PRAX) saw its stock price plummet by 5.19% during intraday trading on Friday, a sharp decline that occurred despite a flurry of positive analyst actions on the company.

The stock's downward movement comes in contrast to multiple analyst reports that raised price targets for Praxis Precision Medicines. Several firms including Deutsche Bank, Jefferies, and Truist Securities increased their target prices for the biopharmaceutical company, which would typically signal bullish sentiment.

However, the negative price action appears to be driven by Wedbush maintaining its "Underperform" rating on the stock. This sell recommendation from Wedbush likely outweighed the positive price target adjustments from other analysts, causing investors to sell shares during the trading session.